Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene
Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform.
Tong JG, Evans AC, Ho ML, Guenther CM, Brun MJ, Judd J, Wu E, Suh J
J Control Release. 2019 Jun 25. pii: S0168-3659(19)30367-0. doi: 10.1016/j.jconrel.2019.06.034. PubMed Article

Plasmids from Article

ID Plasmid Purpose
129024pProvector_AAV2_586_PLGLARRecombinant AAV2 rep/cap plasmid modified to include an 18 amino acid peptide at cap position 586.

Antibodies from Article